CA3241677A1 - Crystalline form of glp-1 receptor agonist and preparation method therefor - Google Patents

Crystalline form of glp-1 receptor agonist and preparation method therefor

Info

Publication number
CA3241677A1
CA3241677A1 CA3241677A CA3241677A CA3241677A1 CA 3241677 A1 CA3241677 A1 CA 3241677A1 CA 3241677 A CA3241677 A CA 3241677A CA 3241677 A CA3241677 A CA 3241677A CA 3241677 A1 CA3241677 A1 CA 3241677A1
Authority
CA
Canada
Prior art keywords
glp
preparation
crystalline form
method therefor
receptor agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3241677A
Other languages
English (en)
French (fr)
Inventor
Gujun XU
Weidong Lu
Junran YANG
Zhenxing DU
Qiyun SHAO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Hengrui Pharmaceutical Co Ltd
Jiangsu Hengrui Pharmaceutical Co Ltd
Original Assignee
Shanghai Hengrui Pharmaceutical Co Ltd
Jiangsu Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Hengrui Pharmaceutical Co Ltd, Jiangsu Hengrui Pharmaceutical Co Ltd filed Critical Shanghai Hengrui Pharmaceutical Co Ltd
Publication of CA3241677A1 publication Critical patent/CA3241677A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3241677A 2021-12-23 2022-12-23 Crystalline form of glp-1 receptor agonist and preparation method therefor Pending CA3241677A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202111586541 2021-12-23
CN202111586541.3 2021-12-23
PCT/CN2022/141407 WO2023116879A1 (zh) 2021-12-23 2022-12-23 一种glp-1受体激动剂的结晶形式及其制备方法

Publications (1)

Publication Number Publication Date
CA3241677A1 true CA3241677A1 (en) 2023-06-29

Family

ID=86901327

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3241677A Pending CA3241677A1 (en) 2021-12-23 2022-12-23 Crystalline form of glp-1 receptor agonist and preparation method therefor

Country Status (10)

Country Link
US (1) US20250049778A1 (enExample)
EP (2) EP4455140B1 (enExample)
JP (1) JP2024547112A (enExample)
KR (1) KR20240125004A (enExample)
CN (1) CN118401518A (enExample)
AU (1) AU2022422997A1 (enExample)
CA (1) CA3241677A1 (enExample)
MX (1) MX2024007907A (enExample)
TW (1) TW202328115A (enExample)
WO (1) WO2023116879A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024340407A1 (en) 2023-09-14 2026-04-23 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
WO2025109387A1 (en) 2023-11-24 2025-05-30 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
WO2025189141A1 (en) 2024-03-08 2025-09-12 Annapurna Bio, Inc. Methods for treating obesity and increasing weight loss

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10934279B2 (en) * 2018-06-13 2021-03-02 Pfizer Inc. GLP-1 receptor agonists and uses thereof
JP2023528565A (ja) * 2020-04-01 2023-07-05 ハンジョウ ジョンメイ フアドン ファーマシューティカル シーオー．，エルティーディー． Ｇｌｐ－１受容体アゴニストの結晶形ａおよびその調製法
PL4157832T3 (pl) * 2020-05-27 2024-12-16 Qilu Regor Therapeutics Inc. Sól i postacie krystaliczne agonistów GLP-1R oraz ich zastosowania
CN119930605A (zh) * 2020-09-01 2025-05-06 江苏恒瑞医药股份有限公司 稠合咪唑类衍生物、其制备方法及其在医药上的应用
WO2022228490A1 (zh) * 2021-04-30 2022-11-03 上海翰森生物医药科技有限公司 多环类衍生物调节剂、其制备方法和应用

Also Published As

Publication number Publication date
KR20240125004A (ko) 2024-08-19
CN118401518A (zh) 2024-07-26
EP4455140B1 (en) 2026-04-01
US20250049778A1 (en) 2025-02-13
EP4455140A1 (en) 2024-10-30
EP4725484A2 (en) 2026-04-15
EP4455140A4 (en) 2025-04-09
JP2024547112A (ja) 2024-12-26
TW202328115A (zh) 2023-07-16
WO2023116879A1 (zh) 2023-06-29
AU2022422997A1 (en) 2024-07-11
MX2024007907A (es) 2024-07-12

Similar Documents

Publication Publication Date Title
CA3241670A1 (en) Pharmaceutically acceptable salt and crystalline form of glp-1 receptor agonist and preparation method therefor
MX2024007907A (es) Forma cristalina del agonista del receptor de peptido 1 similar al glucagon y metodo de preparacion del mismo.
ES3066183T3 (en) 2-(((2,3-dihydrobenzo[b][1,4]dioxan-5-yl)piperidin-1-yl)methyl)-1-((oxetan-2-yl)methyl)-1h-benzo[d]imidazole-6-carboxylic acid derivatives and similar compounds as glp-1 modulators for the treatment of diabetes
ZA202207589B (en) Solid forms of 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d] [1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-benzo[d] imidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt
JP2025160228A5 (enExample)
US6403805B1 (en) 1,3-dihydro-1-(phenylalkyl)-2H-imidazol-2-one derivatves
EE200900043A (et) Tert-butl-(E)-(6-{2-[4-(4-fluorofenl)-6-isopropl-2-[metl(metlsulfonl)amino] primidiin-5-l]vinl}(4R, 6S)-2,2-dimetl[1,3]dioksaan-4-l)atsetaadi valmistamismeetod
PL1651040T3 (pl) Grzybobójcze trójskładnikowe kompozycje substancji czynnych
NO20045120L (no) Triazolderivater som takykininreseptorantagonister
PL213103B1 (pl) Podstawiona pochodna pirazolu, jej zastosowanie i zawierajaca ja kompozycja farmaceutyczna
FI112483B (fi) Menetelmä terapeuttisesti käyttökelpoisten 3-[2-[4-(6-fluori-1,2-bentsisoksatsol-3-yyli) -1-piperidinyyli]etyyli]-2-alkyyli-pyrimidin-4-onijohdannaisten valmistamiseksi
AU2004320025A8 (en) Melanocortin-4 receptor binding compounds and methods of use thereof
PE20050078A1 (es) Derivados de pirrolidona como inhibidores de maob
JP2006501273A5 (enExample)
MX2022015221A (es) Procesos para preparar un inhibidor de cinasa jano 1 (jak1).
JP2007084576A (ja) 神経保護薬
WO2004043920A8 (en) Polymorphs of bicifadine hydrochloride
ES2223893T3 (es) Combinaciones de productos activos fungicidas.
EP1153919A4 (en) SUBSTITUTED ACETYLPYRIDINE DERIVATIVES AND PROCESS FOR THE PREPARATION OF INTERMEDIATES FOR OPTICALLY ACTIVE BETA3 ADRENERGIC RECEPTOR AGONIST USING THE SAME
US4355033A (en) 2-Imino-imidazolidine derivatives
NO20045001L (no) Fremgangsmate for fremstilling av 5-[[2(R)-[1(R)-[3,5-bis(trifluormetyl)fenyl]etoksy]-3(S)-(4-fluorfenyl)-4-morfolinyl]metyl]-1,2-dihydro-3H-1,2,4-triazol-3-on
US5179111A (en) Imidazole derivatives
EP0832071B1 (en) 1,3-dihydro-2h-imidazol-2-one derivatives having pde iv and cytokinin inhibiting activity
CA2364906A1 (en) 4-heterocyclysulfonamidyl-6-methoxy-5-(2-methoxy-phenoxy)-2-pyridyl-pyrimidine derivatives, their preparation and use as endothelin receptor antagonists
US7078430B2 (en) HMG CoA-reductase inhibitors

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W00-W00-W160 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: INACTIVE: COVER PAGE PUBLISHED

Effective date: 20240703

Free format text: ST27 STATUS EVENT CODE: A-1-1-W00-W00-W160 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ARCHIVED EVENT: COVER PAGE PUBLISHED

Effective date: 20240703

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241213

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241213

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251128

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251128

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE

Effective date: 20260305

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260305

R14 Transfer of ownership recorded

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260319